ReviewWorld journal of gastroenterology2021
Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases.
Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Royal Jelly and 10-Hydroxy-2-decenoic Acid Mitigate Alcoholic Fatty Liver Disease in Mice via the Gut-Microbiota-Metabolite Axis.Molecular nutrition & food research · 2026Article
- Quercetin attenuates acute alcohol-induced liver injury in mice by modulating lipid metabolism, oxidative stress, and inflammation.Frontiers in pharmacology · 2026Article
- Characterization of the gut mycobiome in patients with non-alcoholic fatty liver disease and correlations with serum metabolome.BMC microbiology · 2025Article
- Effects of dietary live microbes intake on a newly proposed classification system for steatotic liver disease.Scientific reports · 2025Article
- Gut microbiota dysbiosis in alcoholic fatty liver disease: distinct microbial communities and biochemical alterations.American journal of translational research · 2025Article
- Unraveling the Gut-Liver-Brain Axis: Microbiome, Inflammation, and Emerging Therapeutic Approaches.Mediators of inflammation · 2025Review
- Altered gut microbial profile accompanied by abnormal short chain fatty acid metabolism exacerbates nonalcoholic fatty liver disease progression.Scientific reports · 2024Article
- Lactucin reverses liver fibrosis by inhibiting TGF-β1/STAT3 signaling pathway and regulating short-chain fatty acids metabolism.Scientific reports · 2024Article
- The Role ofMicroorganisms · 2023Review
- Pathogenesis of Alcoholic Fatty Liver a Narrative Review.Life (Basel, Switzerland) · 2023Review
- Dietary Phenolic Compounds: Their Health Benefits and Association with the Gut Microbiota.Antioxidants (Basel, Switzerland) · 2023Review
- Probiotics-FermentedInternational journal of molecular sciences · 2023Article
- Targeted modulation of gut microbiota by traditional Chinese medicine and natural products for liver disease therapy.Frontiers in immunology · 2023Review
- Mesenchymal stem cells-based therapy in liver diseases.Molecular biomedicine · 2022Review
- Intestinal virome: An important research direction for alcoholic and nonalcoholic liver diseases.World journal of gastroenterology · 2022Article
- Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role.Biomedicines · 2022Review
- Screening Potential Drugs for the Development of NAFLD Based on Drug Perturbation Gene Set.Computational and mathematical methods in medicine · 2022Article
- Fecal microbiota transplantation in non-communicable diseases: Recent advances and protocols.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver-gut communication is vital in fatty liver diseases, and gut microbes are the key regulators in maintaining liver homeostasis. Chronic alcohol abuse and persistent overnutrition create dysbiosis in gut ecology, which can contribute to fatty liver disease. In this review, we discuss the gut microbial compositional changes that occur in alcoholic and nonalcoholic fatty liver diseases and how this gut microbial dysbiosis and its metabolic products are involved in fatty liver disease pathophysiology. We also summarize the new approaches related to gut microbes that might help in the diagnosis and treatment of fatty liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.